參股公司上海研諾獲3070萬元增資 司太立(603520.SH)放棄優先認購權
格隆匯2月5日丨司太立(603520.SH)公佈,上海研諾醫藥科技有限公司(簡稱“上海研諾”)為公司的參股公司,目前公司持股比例為8%,近日公司收到上海研諾關於增資的通知,上海研諾擬新增註冊資本66.7392萬元,由北京荷塘生命科學原始創新基金(有限合夥)、連雲港醫藥人才創投基金(有限合夥)、江蘇天優創業投資管理中心(有限合夥)及自然人邱慶以人民幣3070萬元出資認購,該次增資完成後,上述投資者合計將持有增資完成後上海研諾10.9369%的股權。公司放棄該次優先認購權。
該次增資完成後,公司持有的上海研諾股份比例將由8%調整至7.125%,公司放棄上海研諾該次優先認購權不會對公司的正常生產經營活動和財務狀況產生重大影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.